A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group

Russell H. Wiesner, R. W. Busttil, S. McDiarmid, G. B. Klintmalm, R. Goldstein, C. M. Miller, M. Schwartz, Byers Wendell Shaw Jr, J. P. Roberts, M. F. Herbert, C. O. Esquivel, P. Nakazato, R. A.F. Krom, M. Kalayoglu, A. M. D'Alessandro, J. W. Marsh, M. G. Peters, J. Burdick, A. Klein, W. D. Lewis & 5 others R. Jenkins, J. R. Thistlethwaite, J. C. Edmod, S. Gadgil, D. P. Facklam

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

Background. The long-term (5 year) efficacy and safety of tacrolimus (FK506) and cyclosporine were compared in primary liver transplant recipients who participated in a 1-year randomized, multicenter trial and a 4-year follow-up extension study. Methods. A total of 529 patients (263 tacrolimus group, 266 cyclosporine group) were randomized to study drug. Patients were evaluated at 3-month intervals. Patient and graft survival rates, incidence of adverse events, and changes in laboratory and clinical profiles were determined. Results. Cumulative 5-year patient and graft survival rates were comparable for the tacrolimus (79.0%, 71.8%) and cyclosporine (73.1%, 66.4%) groups. However, patient half-life survival was longer for tacrolimus- treated patients (25.1±5.1 years versus 15.2±2.5 years; P=0.049). Improved patient survival with tacrolimus was also observed for hepatitis C-positive patients (78.9% tacrolimus group versus 60.5% cyclosporine group; P=0.041). Both treatments were associated with a low incidence of late acute rejection, late steroid-resistant rejection, and death or graft loss related to rejection. Both treatments demonstrated an acceptable safety profile with maintenance of adequate renal and liver function and a low incidence of malignancy/lymphoproliferative disease and serious infections. Conclusions. Tacrolimus is a safe and effective long-term maintenance immunosuppressive agent in primary liver transplantation.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalTransplantation
Volume66
Issue number4
DOIs
StatePublished - Aug 27 1998

Fingerprint

Tacrolimus
Liver Transplantation
Cyclosporine
Graft Survival
Incidence
Survival Rate
Safety
Survival
Liver
Immunosuppressive Agents
Hepatitis C
Multicenter Studies
Half-Life
Steroids
Transplants
Kidney
Therapeutics
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Transplantation

Cite this

Wiesner, R. H., Busttil, R. W., McDiarmid, S., Klintmalm, G. B., Goldstein, R., Miller, C. M., ... Facklam, D. P. (1998). A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group. Transplantation, 66(4), 493-499. https://doi.org/10.1097/00007890-199808270-00014

A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group. / Wiesner, Russell H.; Busttil, R. W.; McDiarmid, S.; Klintmalm, G. B.; Goldstein, R.; Miller, C. M.; Schwartz, M.; Shaw Jr, Byers Wendell; Roberts, J. P.; Herbert, M. F.; Esquivel, C. O.; Nakazato, P.; Krom, R. A.F.; Kalayoglu, M.; D'Alessandro, A. M.; Marsh, J. W.; Peters, M. G.; Burdick, J.; Klein, A.; Lewis, W. D.; Jenkins, R.; Thistlethwaite, J. R.; Edmod, J. C.; Gadgil, S.; Facklam, D. P.

In: Transplantation, Vol. 66, No. 4, 27.08.1998, p. 493-499.

Research output: Contribution to journalArticle

Wiesner, RH, Busttil, RW, McDiarmid, S, Klintmalm, GB, Goldstein, R, Miller, CM, Schwartz, M, Shaw Jr, BW, Roberts, JP, Herbert, MF, Esquivel, CO, Nakazato, P, Krom, RAF, Kalayoglu, M, D'Alessandro, AM, Marsh, JW, Peters, MG, Burdick, J, Klein, A, Lewis, WD, Jenkins, R, Thistlethwaite, JR, Edmod, JC, Gadgil, S & Facklam, DP 1998, 'A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group', Transplantation, vol. 66, no. 4, pp. 493-499. https://doi.org/10.1097/00007890-199808270-00014
Wiesner, Russell H. ; Busttil, R. W. ; McDiarmid, S. ; Klintmalm, G. B. ; Goldstein, R. ; Miller, C. M. ; Schwartz, M. ; Shaw Jr, Byers Wendell ; Roberts, J. P. ; Herbert, M. F. ; Esquivel, C. O. ; Nakazato, P. ; Krom, R. A.F. ; Kalayoglu, M. ; D'Alessandro, A. M. ; Marsh, J. W. ; Peters, M. G. ; Burdick, J. ; Klein, A. ; Lewis, W. D. ; Jenkins, R. ; Thistlethwaite, J. R. ; Edmod, J. C. ; Gadgil, S. ; Facklam, D. P. / A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group. In: Transplantation. 1998 ; Vol. 66, No. 4. pp. 493-499.
@article{026aac57f9ed4f679f0743f0a4735b82,
title = "A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group",
abstract = "Background. The long-term (5 year) efficacy and safety of tacrolimus (FK506) and cyclosporine were compared in primary liver transplant recipients who participated in a 1-year randomized, multicenter trial and a 4-year follow-up extension study. Methods. A total of 529 patients (263 tacrolimus group, 266 cyclosporine group) were randomized to study drug. Patients were evaluated at 3-month intervals. Patient and graft survival rates, incidence of adverse events, and changes in laboratory and clinical profiles were determined. Results. Cumulative 5-year patient and graft survival rates were comparable for the tacrolimus (79.0{\%}, 71.8{\%}) and cyclosporine (73.1{\%}, 66.4{\%}) groups. However, patient half-life survival was longer for tacrolimus- treated patients (25.1±5.1 years versus 15.2±2.5 years; P=0.049). Improved patient survival with tacrolimus was also observed for hepatitis C-positive patients (78.9{\%} tacrolimus group versus 60.5{\%} cyclosporine group; P=0.041). Both treatments were associated with a low incidence of late acute rejection, late steroid-resistant rejection, and death or graft loss related to rejection. Both treatments demonstrated an acceptable safety profile with maintenance of adequate renal and liver function and a low incidence of malignancy/lymphoproliferative disease and serious infections. Conclusions. Tacrolimus is a safe and effective long-term maintenance immunosuppressive agent in primary liver transplantation.",
author = "Wiesner, {Russell H.} and Busttil, {R. W.} and S. McDiarmid and Klintmalm, {G. B.} and R. Goldstein and Miller, {C. M.} and M. Schwartz and {Shaw Jr}, {Byers Wendell} and Roberts, {J. P.} and Herbert, {M. F.} and Esquivel, {C. O.} and P. Nakazato and Krom, {R. A.F.} and M. Kalayoglu and D'Alessandro, {A. M.} and Marsh, {J. W.} and Peters, {M. G.} and J. Burdick and A. Klein and Lewis, {W. D.} and R. Jenkins and Thistlethwaite, {J. R.} and Edmod, {J. C.} and S. Gadgil and Facklam, {D. P.}",
year = "1998",
month = "8",
day = "27",
doi = "10.1097/00007890-199808270-00014",
language = "English (US)",
volume = "66",
pages = "493--499",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the United States FK506 study group

AU - Wiesner, Russell H.

AU - Busttil, R. W.

AU - McDiarmid, S.

AU - Klintmalm, G. B.

AU - Goldstein, R.

AU - Miller, C. M.

AU - Schwartz, M.

AU - Shaw Jr, Byers Wendell

AU - Roberts, J. P.

AU - Herbert, M. F.

AU - Esquivel, C. O.

AU - Nakazato, P.

AU - Krom, R. A.F.

AU - Kalayoglu, M.

AU - D'Alessandro, A. M.

AU - Marsh, J. W.

AU - Peters, M. G.

AU - Burdick, J.

AU - Klein, A.

AU - Lewis, W. D.

AU - Jenkins, R.

AU - Thistlethwaite, J. R.

AU - Edmod, J. C.

AU - Gadgil, S.

AU - Facklam, D. P.

PY - 1998/8/27

Y1 - 1998/8/27

N2 - Background. The long-term (5 year) efficacy and safety of tacrolimus (FK506) and cyclosporine were compared in primary liver transplant recipients who participated in a 1-year randomized, multicenter trial and a 4-year follow-up extension study. Methods. A total of 529 patients (263 tacrolimus group, 266 cyclosporine group) were randomized to study drug. Patients were evaluated at 3-month intervals. Patient and graft survival rates, incidence of adverse events, and changes in laboratory and clinical profiles were determined. Results. Cumulative 5-year patient and graft survival rates were comparable for the tacrolimus (79.0%, 71.8%) and cyclosporine (73.1%, 66.4%) groups. However, patient half-life survival was longer for tacrolimus- treated patients (25.1±5.1 years versus 15.2±2.5 years; P=0.049). Improved patient survival with tacrolimus was also observed for hepatitis C-positive patients (78.9% tacrolimus group versus 60.5% cyclosporine group; P=0.041). Both treatments were associated with a low incidence of late acute rejection, late steroid-resistant rejection, and death or graft loss related to rejection. Both treatments demonstrated an acceptable safety profile with maintenance of adequate renal and liver function and a low incidence of malignancy/lymphoproliferative disease and serious infections. Conclusions. Tacrolimus is a safe and effective long-term maintenance immunosuppressive agent in primary liver transplantation.

AB - Background. The long-term (5 year) efficacy and safety of tacrolimus (FK506) and cyclosporine were compared in primary liver transplant recipients who participated in a 1-year randomized, multicenter trial and a 4-year follow-up extension study. Methods. A total of 529 patients (263 tacrolimus group, 266 cyclosporine group) were randomized to study drug. Patients were evaluated at 3-month intervals. Patient and graft survival rates, incidence of adverse events, and changes in laboratory and clinical profiles were determined. Results. Cumulative 5-year patient and graft survival rates were comparable for the tacrolimus (79.0%, 71.8%) and cyclosporine (73.1%, 66.4%) groups. However, patient half-life survival was longer for tacrolimus- treated patients (25.1±5.1 years versus 15.2±2.5 years; P=0.049). Improved patient survival with tacrolimus was also observed for hepatitis C-positive patients (78.9% tacrolimus group versus 60.5% cyclosporine group; P=0.041). Both treatments were associated with a low incidence of late acute rejection, late steroid-resistant rejection, and death or graft loss related to rejection. Both treatments demonstrated an acceptable safety profile with maintenance of adequate renal and liver function and a low incidence of malignancy/lymphoproliferative disease and serious infections. Conclusions. Tacrolimus is a safe and effective long-term maintenance immunosuppressive agent in primary liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0032572809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032572809&partnerID=8YFLogxK

U2 - 10.1097/00007890-199808270-00014

DO - 10.1097/00007890-199808270-00014

M3 - Article

VL - 66

SP - 493

EP - 499

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -